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Human life expectancy in developed countries has increased steadily for over 150 years, through
improvements in public health and lifestyle. More people are hence living long enough to suffer
age-related loss of function and disease, and there is a need to improve the health of older people.
Ageing is a complex process of damage accumulation, and has been viewed as experimentally and
medically intractable. This view has been reinforced by the realization that ageing is a disadvantageous
trait that evolves as a side effect of mutation accumulation or a beneﬁt to the young, because of the
decline in the force of natural selection at later ages. However, important recent discoveries are that
mutations in single genes can extend lifespan of laboratory model organisms and that the mechanisms
involved are conserved across large evolutionary distances, including to mammals. These mutations
keep the animals functional and pathology-free to later ages, and they can protect against speciﬁc
ageing-related diseases, including neurodegenerative disease and cancer. Preliminary indications
suggest that these new ﬁndings from the laboratory may well also apply to humans. Translating
these discoveries into medical treatments poses new challenges, including changing clinical thinking
towards broad-spectrum, preventative medicine and ﬁnding novel routes to drug development.
Keywords: ageing; lifespan; ageing-related disease; geriatrics; preventative medicine;
nutrient-sensing pathways
1. INTRODUCTION
The increase in life expectancy in human populations
worldwide is a triumph of biomedical research. Survi-
val rates started to increase in the mid-nineteenth
century, because of improvements in public health,
particularly clean water, immunization and antibiotics,
and also because of other improvements in lifestyle
such as better housing. The rate of increase in life
expectancy in most countries does not yet show any
sign of slowing and, indeed, is greatest in older age
classes; we cannot yet see what any intrinsic limit to
human life expectancy will be (Wilmoth 2000;
Oeppen & Vaupel 2002).
For a given age, health now is better than it was 150
years ago, but this welcome change is also producing
great challenges. Many of these are socio-economic,
concerning issues such as work force participation
and affordability of pension schemes. Paradoxically,
there is also a major medical problem. The improve-
ment in individual health means that larger numbers
of individuals reach older ages, and hence live long
enough to suffer from ageing-related disease and loss
of function. All of the major killer diseases, including
cardiovascular disease, cancer and dementia, are
strongly age related. The predominant burden of
ill-health is now falling on the older section of the
population and, both for health beneﬁts to ageing
individuals and economic beneﬁts to the societies in
which they live, we urgently need to discover means
of improving health during ageing. Fortunately,
major scientiﬁc opportunities have opened up in
research into ageing and bring with them the enticing
prospect of a broad-spectrum, preventative, medicine
for diseases of ageing. However, taking the fruits of
these scientiﬁc discoveries to the ageing human
population may not be straightforward.
From the biological standpoint, the major features
of ageing are an intrinsic decline in function during
adulthood, leading to a drop in fecundity and
increased likelihood of death (Finch 1990). Ageing is
not inevitable and, indeed, some organisms seem not
to age at all or to do so very slowly. Some even show
an increase in fecundity or survival rate over at least
part of adulthood. Ageing is particularly apparent in
organisms where growth is completed before repro-
duction commences, such as insects, birds and many
mammals, including humans (Vaupel et al. 2004;
Baudisch 2005). The major laboratory model organ-
isms used for research into ageing, namely budding
yeast Saccharomyces cerevisiae, the nematode worm
Caenorhabditiselegans,thefruitﬂyDrosophilamelanogaster
and the mouse Mus musculus, all fall into this category
and, in this sense at least, are good models for human
ageing.
The phenotypes associated with ageing have been
best studied in humans and are complex (Martin
2002). Within single tissues, multiple types of damage
and pathology increase in incidence with age, and the
spectrum of changes differs between tissues. The
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between individuals (Finch & Kirkwood 1999). This
complexity and variability have led to a picture of the
ageing process as intractable, for both experimental
analysis and medical intervention. Indeed, it could be
concluded that there is no single ageing process;
rather, during ageing, a large number of independent
and stochastic processes of damage accumulation
occur in parallel, with little or no common causality.
Amelioration of the impact of one type of ageing-related
damage would, if this scenario is correct, leave the
majority unaffected and would hence have little impact
on overall ageing-related decline. This view of ageing
permeates medicine to the present day. Geriatrics is lar-
gely a primary care medical speciality, with little input
from basic and clinical research, unlike speciﬁc ageing-
related diseases such as cancer, cardiovascular disease
and neurodegeneration, which are all associated with
sizeableandwell-fundedresearchcommunities.Speciﬁc
diseases of ageing are generally viewed as medically
tractable, unlike the ageing process itself.
The idea that ageing is difﬁcult to modify has until
recently been reinforced by work on its evolution. Evol-
utionary biologists have long been intrigued by ageing,
because it is a deleterious trait, but it nonetheless
shows great diversity in the natural world. After various
ideas of a possible beneﬁt of ageing to family groups or
whole species were largely discredited (Kirkwood &
Cremer 1982), the key insight came with the realization
that, because of extrinsic causes of mortality such as dis-
ease, predation and accidents, the force of natural
selection weakens for older age classes, because fewer
individuals succeed in reaching them (Haldane 1941;
Medawar 1946, 1952). A substantial body of theoretical
analysis, experimentation and comparative work led to
the conclusion that ageing can hence evolve as a side
effect, either of pressure of new mutations that reduce
fecundity or survival probability later in life or of
mutations that have beneﬁcial effects in the young
(Medawar 1952; Williams 1957; Hamilton 1966;
Hughes & Reynolds 2005; Partridge & Gems 2006;
Moorad & Promislow 2008). As far as we know, no
genes have evolved to cause ageing. Unlike develop-
ment, there is no well-oiled hierarchy of genetic
regulation to ensure that ageing happens in the right
tissues and at the right times. Instead, it is an unregu-
lated side effect of the failure of natural selection to
maintain function at the later ages that few individuals
reach in nature (Partridge &Gems2002a).Thesetheor-
etical and practical insights have led to the conclusion
that ageing is likely to be a highly polygenic trait,
since many genes are involved in assurance of survival
during adulthood and in promoting fecundity.
The complexity of the ageing phenotype and the
realization that it is an evolutionary side effect, rather
than an adaptive process, led to the widespread
assumption that mutations in single genes were unli-
kely to be capable of slowing down ageing.
Furthermore, it seemed improbable that mechanisms
of ageing would be the same in different kinds of
organisms. If different human tissues acquire such
different forms of damage and pathology during
ageing, presumably as a result of the different types
of insults of daily living that they encounter then, by
the same token, organisms with very different life
styles would be expected to encounter different
sources of damage (Partridge & Gems 2002b).
2. SINGLE-GENE MUTATIONS THAT EXTEND
THE LIFESPAN OF LABORATORY ANIMALS
Perhaps the single most important advance in ageing
research in recent years has been discovery of
mutations in single genes that extend the lifespan of
laboratory animals. They ﬁrst came to light as a
result of a systematic chemical mutagenesis screen
for lifespan-extending mutations in C. elegans (Klass
1983). Subsequent work with these mutations
(Friedman & Johnson 1988), and further screening
(Kenyon et al.1 9 9 3 ), revealed that it was possible to
double the lifespan of the worm with a mutation in a
single gene. Furthermore, rather than solely prolonging
the moribund period at the end of the life,the mutations
caused the worms to remain healthy and youthful for
longer (Kenyon et al. 1993). The mutated genes were
discovered to encode components of an invertebrate
insulin/insulin-like growth-factor-like signalling (IIS)
pathway (Kimura et al. 1997; Lin et al.1 9 9 7 ; Ogg et al.
1997). These ﬁndings came as a considerable surprise,
because a signalling pathway previously associated with
control of growth and metabolism in mammals now
turned out to play a role in determination of lifespan in
a distantly related invertebrate.
Mutations with similar effects on lifespan were soon
discovered in other model organisms. For instance, a
similar screening effort in yeast led to the discovery
that over-expression of a protein deacetylase, SIR2,
extended replicative lifespan (Sinclair & Guarente
1997; Kaeberlein et al. 1999), while mutations in
methuselah in Drosophila increased ﬂy lifespan (Lin
Seroude & Benzer 1998). Likewise, in the mouse,
mutations in genes encoding transcription factors
involved in the development of the pituitary gland
resulted in long-lived dwarf mice (Brown-Borg et al.
1996). By the late 1990s, it was ﬁrmly established
that lifespan of these model organisms could indeed
be extended by mutations in single genes.
It had also been known since the 1930s that an
environmental intervention, dietary restriction (DR),
could produce substantial increases in lifespan in lab-
oratory rodents (McCay et al. 1935). Although the
exact mechanisms at work still await full elucidation,
detailed study of DR rodents has demonstrated a
broad-spectrum improvement in health and a delay
in or amelioration of the impact of a wide range of
ageing-related diseases (Masoro 2005, 2006). For
instance, the animals are protected against cancer, cat-
aract, diabetes, motor decline, osteoporosis and
nephropathy (Weindruch & Walford 1988). These
ﬁndings suggested that, in principle, multiple aspects
of the ageing phenotype could be simultaneously
ameliorated by a single intervention, albeit, in the
case of DR, a complex one.
3. EVOLUTIONARY CONSERVATION
The ultimate aim of biomedical research into ageing
with animals is to improve the health of the older
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organisms have been key to understanding many
other aspects of human biology. Embryonic develop-
ment, the cell cycle, the functioning of the nervous
system, cellular metabolism and many other processes
have often been investigated by proceeding from sim-
pler organisms to more complex ones. This process
works because of evolutionary conservation of genes
and their functions over the large evolutionary dis-
tances involved. Indeed, it is often possible to
introduce a human gene into yeast or Drosophila and
ﬁnd that it functions quite normally there. However,
because ageing is not an adaptive trait and because
different kinds of organisms are exposed to different
kinds of stress and damage, there has been a good
reason to doubt that this kind of evolutionary
conservation will apply to the ageing process.
DR extends lifespan not only in rodents but also in
a wide range of distantly related organisms, including
yeast (Jiang et al. 2000; Lin et al. 2000), C. elegans
(Klass 1977; Lakowski & Hekimi 1998; Greer et al.
2007; Kennedy et al. 2007; Smith et al. 2008a) and
Drosophila (Chippindale et al. 1993; Chapman &
Partridge 1996). Indeed recent work has demonstrated
that DR increases lifespan in rhesus monkeys
(Holloszy & Fontana 2007; Mattison et al. 2007;
Colman et al. 2009) and short-term DR can produce
improvements in function in humans (e.g. Holloszy &
Fontana 2007). Because the details of the mechanisms
by which DR extends lifespan are not fully elucidated
for any organism, it is not clear whether this is a case
of evolutionary conservation or whether instead there
has been evolutionary convergence (Mair & Dillin
2008).
It was originally suspected that extension of lifespan
by reduced IIS might turn out to be a worm
peculiarity. This was because mutations in genes in
the IIS pathway can also cause the worms to enter a
type of developmental arrest (dauer), normally seen
only in response to low food or crowding (Riddle &
Albert 1997). Dauer larvae are long lived, and the
long life of IIS mutant adult worms could therefore
have been a result of re-expression in the adult of the
genes that make the dauer larva long lived (Kenyon
et al. 1993), a speculation conﬁrmed by studies of
gene expression (McElwee et al. 2003, 2004). Most
organisms do not undergo this type of developmental
arrest and might therefore lack the mechanisms for
long life seen in dauer larvae. However, an important
recent discovery has been that the IIS pathway
has an evolutionarily conserved role in determining
longevity; mechanisms of ageing therefore are, at
least to some extent, ‘public’ or shared (Partridge &
Gems 2002b). Remarkably, mutations in the single
Drosophila insulin receptor (Tatar et al. 2001) and insu-
lin receptor substrate (Clancy et al. 2001) proved to
extend lifespan in the ﬂy. Furthermore, mutations in
the genes encoding both the insulin (Bluher et al.
2003) and Igf-1 receptor (Holzenberger et al. 2003)
extended lifespan in the mouse. Subsequent work
with all three organisms has amply conﬁrmed the evo-
lutionarily conserved role of this signalling pathway
(Russell & Kahn 2007; Piper et al. 2008; Taguchi &
White 2008). Early evidence from population–genetic
association studies has also started to implicate
the pathway in determination of human lifespan
(Mooijaart et al. 2005; Kuningas et al. 2007; Willcox
et al. 2008).
Evidence for evolutionary conservation of genetic
determinants of lifespan is at present strongest for
the IIS pathway, but others are likely to lengthen the
list. For instance, the effect of elevated expression of
SIR2 in yeast appears to be conserved in C. elegans
(Tissenbaum & Guarente 2001) and Drosophila
(Rogina & Helfand 2004), and mutations in genes
encoding components of the target of rapamycin
(TOR) pathway also extend the lifespan in all
four organisms (Jia et al. 2004; Kapahi et al. 2004;
Kaeberlein et al. 2005; Hansen et al. 2007; Pan et al.
2007; Sheaffer et al. 2008; Smith et al. 2008b;
Harrison et al. 2009). Sufﬁcient single-gene mutations
that extend lifespan in yeast and C. elegans have now
been identiﬁed to allow a quantitative estimate of
the degree of evolutionary conservation of genetic
modiﬁers of ageing between these two organisms
(Smith et al. 2008b). In C. elegans, loss of function of
a set of approximately 276 genes, or altered function
of their protein products, has proved to extend
lifespan. A set of 103 yeast orthologues of 78 of
these 276 worm genes could be identiﬁed on the
basis of sequence similarity, and deletion of 76 of
these resulted in viable yeast strains. Eleven of the
76 were long lived, a proportion 4.3 times higher
than would be expected from deletion of the same
number of randomly selected yeast genes. Many of
the genes with a conserved role in ageing in these
two organisms are involved in protein synthesis
(Smith et al. 2008b), a process whose importance to
ageing has recently been demonstrated by experimen-
tal studies in C. elegans (Hansen et al. 2007; Pan et al.
2007). This strong signal of evolutionary conservation
between these two distantly related organisms suggests
that future studies of the role of protein synthesis in
ageing in the fruitﬂy and the mouse would pay
dividends.
Although there is abundant evidence for an evolu-
tionarily conserved role for IIS and other pathways in
determination of lifespan, it remains to be seen how
deep that conservation penetrates. Even at the level
of signalling mechanisms, there may be considerable
variation between different organisms as is implied,
for instance, by the presence of much larger numbers
of insulin ligands in the worm (38) and the ﬂy (7)
than in mammals. In addition, similar changes in sig-
nalling in different organisms may have very different
outcomes because of differences in structure and
physiology. Of particular importance for IIS, insulin
resistance and failure in insulin production can result
in diabetes in mammals, with its consequent vascular
damage, while the invertebrates, with their open circu-
latory systems, can probably better tolerate elevated
blood sugar. Only a narrow range of alterations in
IIS may therefore increase mammalian lifespan.
There is some evidence for evolutionary conservation
of the biochemical mechanisms by which altered IIS
extends lifespan in different organisms. For instance,
proﬁling of gene expression in long-lived, IIS mutant
worms, ﬂies and mice showed increased expression
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iﬁcation pathway, important in the elimination of
lipophilic endobiotics, xenobiotics and drugs (McEl-
wee et al. 2007; Sykiotis & Bohmann 2008; Tullet
et al. 2008). Subsequent work with a key transcrip-
tional regulator of the pathway has demonstrated
experimentally that increasing its activity can increase
lifespan in both C. elegans and Drosophila (McElwee
et al. 2007; Sykiotis & Bohmann 2008; Tullet et al.
2008). Cellular detoxiﬁcation may therefore be an
important process for protection against the effects
of ageing in all three organisms, although whether
the toxins involved are the same or different remains
to be determined.
So far we have only scratched the surface of the
mechanisms at work in lifespan extension. Nonethe-
less, these new ﬁndings have opened up the promise
of a major scientiﬁc opportunity, to use the invert-
ebrates and the mouse to understand human ageing,
exploiting the full range of analytical tools available
in the model organisms.
4. RISK AND DAMAGE
Slowing down ageing is not the only means by which
lifespan can be extended. The ageing process is
characterized by a decline in function with advancing
age during adulthood; the state of the organisms pro-
gressively worsens. One might therefore expect that
an intervention that extended lifespan by amelioration
of the ageing process would do so by slowing down the
rate at which state worsens with age (Finch 1990). A
simple and direct way of assessing the state of a popu-
lation is to measure mortality rate, which is, to a ﬁrst
approximation, the proportion of individuals that
enter each age class that die during it. Mortality
rates generally show a roughly exponential increase
with age in humans and the laboratory model organ-
isms and can hence be described in terms of
two important parameters: the initial, baseline mor-
tality rate, which is age independent, and the rate at
which mortality rate increases with age (Finch 1990;
Pletcher et al. 2000). Interventions, genetic and
environmental, that increase lifespan can do so by
decreasing either or both of these parameters (Pletcher
et al. 2000). A reduction in the slope of a mortality
trajectory is what would be expected if lifespan were
increased by a reduction in the rate of ageing itself
(Finch 1990).
One intervention that clearly can slow down the rate
of ageing is lowered temperature for ectotherms. In
Drosophila, lowered temperature increases lifespan
entirely by lowering the slope of the mortality trajec-
tory, with no effect on the initial mortality rate
(Mair et al. 2003). These ﬂies are too small to thermo-
regulate and are thus forced to adopt ambient
temperature. Lowering of the slope of the mortality
trajectory in cooler environments is consistent with
the idea that lowered temperature decreases the rate
of most or all molecular processes in the organism,
including the rate of ageing. In support of this view,
when ﬂies are switched between temperatures, the
subsequent slope of the mortality trajectory immedi-
ately changes to that characteristic of ﬂies kept
permanently in the new thermal regime (Mair et al.
2003). The ﬂies therefore bear the permanent imprint
of their thermal history, with warmer temperatures
leading to the accumulation of a higher level of irre-
versible damage, and no acute effect of temperature
on mortality rate. Lowered temperature thus decreases
the rate of ageing in Drosophila and provides a useful
benchmark for an intervention that does so.
Rather than decreasing the rate of ageing, the
increase in lifespan in industrialized human societies
has occurred by a reduction in baseline mortality
rates, with no reduction in the slope of the mortality
trajectory (Wilmoth 2000). This suggests that overall
health, at all ages, has improved, but that the under-
lying process of accumulation of ageing-related
damage has not been ameliorated. This ﬁnding
leaves open the question of the time course of these
effects. For instance, events early in life or even
in utero could have a lifelong impact on health, and
there could also be more acute effects of recent and
current environments. To measure such timing effects,
it is necessary to compare individuals with currently
similar circumstances but different past environments,
and vice versa.
Interestingly, DR can have a similar effect on mor-
tality trajectories to that associated with the increase
in human lifespan expectancy; DR extends life in
Drosophila entirely by reducing the initial mortality
rate with no lowering of its slope (Pletcher et al.
2000). Similar ﬁndings have been reported for DR in
mice (Weindruch et al. 1986; Hursting et al. 1994),
and for one form of DR in C. elegans (Smith et al.
2008a), suggesting that, in these three organisms at
least, DR may not slow down the rate of ageing and
may instead increase lifespan through a different
mechanism. Indeed, experimental reversal of the
nutritional status of ﬂies has shown that the effect of
DR on mortality rate is acute. Later onset DR leads,
within 48 h, to a switch in subsequent mortality rates
to those of permanently DR ﬂies (Mair et al. 2003).
Likewise, previously DR ﬂies that are switched to full
feeding at later ages show a rapid increase in mortality
rates to those characteristic of ﬂies that are perma-
nently fully fed. DR and fully fed ﬂies thus age at
the same rate, and DR instead extends lifespan by
reducing the acute risk of death.
There is little information on the timing of the effects
of single-gene mutations on mortality rate. In C. elegans,
switches in IIS status using double stranded RNA inter-
ference have shown that the pathway acts speciﬁcally
during adulthood to determine adult survival (Dillin
Crawford & Kenyon 2002), but more detailed timing
information is not yet available. In Drosophila,a ni n d u -
cible system for gene expression was used to show that,
at least up to a month of adult age, the IIS pathway acts
acutely to determine mortality rate, similar to DR
(Giannakou et al.2 0 0 7 ). It will be important to deter-
mine whether this kind of acute effect on mortality
rate applies to other pathways that determine lifespan
and, in particular, whether it extends to mammals.
But it is already clear that, in principle, lifespan can
be extended by making the animal less likely to die of
the damage that it has accumulated, rather than by
reducing the accumulation of damage.
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It has long been known that DR in rodents reduces the
impact of a wide range of ageing-related diseases, and
it has also been shown to reduce the impact of proteo-
toxicity in C. elegans (Steinkraus et al. 2008). Because
the single-gene mutations that extend lifespan have
only been discovered recently, less information is avail-
able, but already it seems that aspects of function and
health during ageing are improved. For instance,
associative learning is more strongly maintained at
later ages in long-lived IIS mutants worms (Murakami
et al. 2005), while locomotor function is better main-
tained during ageing in long-lived IIS mutant ﬂies
(Martin & Grotewiel 2006). Loss of the insulin recep-
tor substrate 1 in the mouse also protects against loss
of glucose homeostasis, immune and motor function
and reduces the impact of osteoporosis, cataract and
ulcerative dermatitis (Selman et al. 2008). As well as
maintaining function and health during ageing, life-
span-extending mutations can protect against the
pathology associated with speciﬁc genetic models of
ageing-related disease. For instance, recent work with
C. elegans has revealed that mutations in IIS that
increase lifespan can reduce the pathology associated
with genetic models of cancer (Pinkston et al. 2006;
Pinkston-Gosse & Kenyon 2007) and of proteotoxi-
city-induced neurodegeneration (Cohen et al. 2006;
Pinkston et al. 2006; Steinkraus et al. 2008). Further-
more, mutations in IIS in the mouse can protect
against the pathology associated with speciﬁc genetic
models of Alzheimer’s disease (Freude et al. 2009;
Killick et al. 2009). The indications are, therefore,
that these interventions can produce an improvement
in health and function in diverse tissue systems and
reduce the impact of ageing-related diseases with
diverse aetiology (Butler et al. 2008).
The implication of these ﬁndings is that protection
against the ageing process results in protection against
diverse, ageing-related diseases. The ageing process
itself is acting as the major risk factor for these con-
ditions. This realization leads in turn to the
conclusion that there is an underlying commonality
in the aetiology of these ageing-related diseases,
despite their diverse manifestations. It is early days
yet, and a great deal more work needs to be done to
understand exactly how the ageing process increases
vulnerability to these diseases. We need also to under-
stand how transition into loss of function and disease
occurs, and how a single environmental intervention
or gene mutation can have such broad-spectrum
effects. A key challenge in the biology of ageing, and
one that is increasingly being recognized, is to under-
stand how events at different levels of organization
contribute to loss of function during organismal
ageing and to eventual death (Kirkwood 2008;
Murphy & Partridge 2008). Presumably, in a complex
chain of events, damage to macromolecules and orga-
nelles causes decline in cellular function and cell loss,
which in turn compromise the function of tissues. Dys-
functional tissues could in turn act systemically to
cause stress and eventual damage to other tissues,
which could to some extend cause a correlation in
the rate of ageing of different parts of the body
within an individual. Many of these key changes may
be susceptible to acute intervention, similar to the
effects of DR in the invertebrate model organisms.
At some point, irreversibility must enter the system,
because of the emergence of lethal, ageing-related
disease that cannot be rescued by the intervention
(Partridge Pletcher & Mair 2005b). Identifying,
experimentally investigating and modelling these tem-
poral changes and their dynamics will require
considerable effort, and in the near future much
more experimental work will be needed to bring
understanding of these systems to a level of maturity
where productive modelling will be possible.
6. WILL LIFESPAN EXTENSION IN
LABORATORY MODEL ORGANISMS
BE RELEVANT TO HUMAN AGEING?
The ﬁndings from the model organisms have a clear,
potential message for the medical treatment of
ageing-related diseases (Butler et al. 2008). At present,
these diseases are treated piecemeal by different medi-
cal specialists, because they are regarded as separate
medical problems. Patients themselves generally visit
a clinician because they have a speciﬁc medical pro-
blem, not because they are old. However, if in
humans, also, protection against the effect of ageing
can delay or ameliorate diverse ageing-related diseases,
then a quite different approach to the health of older
people would pay dividends. A broad-spectrum,
preventative approach would be required, with individ-
uals who reached a certain age being treated even in
the absence of any ageing-related disease. Further-
more, if the effects of a beneﬁcial intervention were
acute, as has occurred in some of the animal models,
then it would need to be applied for the rest of life.
Clinical trials would also need to be conducted for a
protracted period. All of these features would pose sig-
niﬁcant obstacles to translating the ﬁndings from basic
science into drug development and clinical practice.
However, if the ﬁndings from the animal models
turn out to apply to humans, then a major opportunity
could be missed. What, then, is the likelihood that
evolutionary conservation of the mechanisms will
extend to our own species?
There are some obvious questions about lifespan
extension in animal models that have a bearing on
likely relevance to humans. If these single gene
mutations can produce such broad-spectrum beneﬁts
to health, then why is the mutant not the wild-type?
These mutants must have side effects that mean that
they are not the ﬁttest genotype in the wild. Some
mutants that extend lifespan clearly delay or reduce
fecundity, as does DR (Partridge et al. 2005a).
However, it is also clear that, at least in the laboratory,
impaired fecundity is not necessary for extension of
lifespan by some single-gene mutations (Partridge
et al. 2005a), although some claims that this is the
case may have been based on failing to measure all
aspects of fecundity or doing so in benign circum-
stances (Rogina et al. 2000; Walker et al. 2000;
Marden et al. 2003; Jenkins et al. 2004). Nature is in
general a more exacting place than the laboratory,
where the animals are kept largely free of
pathogens, have an abundant and highly accessible
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with conspeciﬁcs. However, many of these consider-
ations apply also to humans in developed countries.
It will be important to evaluate what are the negative
effects of single-gene mutations that make them
disadvantageous under natural circumstances, to
understand how important these might be for
humans. It should also be borne in mind that medical
interventions into ageing are likely to be applied only
later in the lifespan, when some of the negative side
effects may no longer be relevant, and it has already
been demonstrated that administration of a TOR
inhibitor, rapamycin, later in life in mice can extend
the lifespan (Harrison et al. 2009). The prospects
that the ﬁndings from the laboratory will prove to be
of medical relevance to humans therefore look
promising.
Humans are, obviously, much longer lived than any
of the laboratory model organisms. This could have a
bearing on the extent to which interventions could
ameliorate the effects of ageing, or not. It is notable
that many of the genes that have so far come to light
as affecting longevity in the laboratory are involved in
nutrient sensing pathways, which contribute to match-
ing the growth and reproductive rate of the animals to
their nutritional status. Human growth and reproduc-
tion respond to nutrients, but not to such an extent as
do those of the laboratory model organisms, which are
all subject to boom and bust conditions in nature.
However, even if human lifespan is not as plastic as
that of laboratory animals, the same may not be true
for ageing-related disease. The aim of this research is
to improve human health during ageing, not to
extend lifespan per se, and it remains to be seen to
what extent this is going to be possible.
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